Direkt zum Inhalt
Merck
Alle Fotos(1)

Wichtige Dokumente

Gesamtdokumentation anzeigen

D3821

Sigma-Aldrich

Devazepide

≥98% (HPLC), powder

Synonym(e):

(S)-N-(2,3-Dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)indole-2-carboxamide, L-364,718, MK 329

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise

Größe auswählen

5 MG
127,40 €
25 MG
720,00 €

127,40 €

Listenpreis182,00 €Sparen Sie 30%

Versandbereit am07. April 2025Details

Bulk-Bestellung anfordern
Alle Fotos(1)

Größe auswählen

Ansicht ändern
5 MG
127,40 €
25 MG
720,00 €

About This Item

Empirische Formel (Hill-System):
C25H20N4O2
CAS-Nummer:
103420-77-5
Molekulargewicht:
408.45
MDL-Nummer:
MFCD00864500
UNSPSC-Code:
12352200
PubChem Substanz-ID:
329798778
NACRES:
NA.77

127,40 €

Listenpreis182,00 €Sparen Sie 30%

Versandbereit am07. April 2025Details

Bulk-Bestellung anfordern

Qualitätsniveau

100

Assay

≥98% (HPLC)

Form

powder

Lagerbedingungen

desiccated

Farbe

white to off-white

Löslichkeit

DMSO: >5 mg/mL

Ersteller

Merck & Co., Inc., Kenilworth, NJ, U.S.

Lagertemp.

2-8°C

SMILES String

CN1C(=O)[C@@H](NC(=O)c2cc3ccccc3[nH]2)N=C(c4ccccc4)c5ccccc15

InChI

1S/C25H20N4O2/c1-29-21-14-8-6-12-18(21)22(16-9-3-2-4-10-16)27-23(25(29)31)28-24(30)20-15-17-11-5-7-13-19(17)26-20/h2-15,23,26H,1H3,(H,28,30)/t23-/m1/s1

InChIKey

NFHRQQKPEBFUJK-HSZRJFAPSA-N

Allgemeine Beschreibung

Devazepide is derived from asperlicin by chemical modification and has the benzodiazepine backbone.[1]

Anwendung

Devazepide has been used as a cholecystokinin receptor 1 (CCK1R) antagonist in human embryonic kidney 293T cells[2] and in human pancreatic slices.[3]

Biochem./physiol. Wirkung

Devazepide is a CCK1 (CCK-A) receptor antagonist and a CCK8 antagonist.
Devazepide is a CCK1 receptor antagonist.
Devazepide is a cholecystokinin octapeptide (CCK1) (CCK-A) receptor antagonist. It inhibits CCK binding to peripheral-type receptor (CCK-A). Devazepide reverses the cholecystokinin octapeptide (CCK-8) based antagonism towards morphine.[4]

Leistungsmerkmale und Vorteile

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Piktogramme

Skull and crossbones
GHS06

Signalwort

Danger

H-Sätze

H300

Gefahreneinstufungen

Acute Tox. 1 Oral

Lagerklassenschlüssel

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number
010M4600V
0000144613
0000144613
0000144617

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Suche nach COA

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 2

1 of 2

Cytotoxicity Detection KitPLUS (LDH) sufficient for 400 multiwell tests (04744926001), sufficient for 2,000 multiwell tests (04744934001), kit of 1 (4 components), suitable for protein quantification, suitable for cell analysis, detection

Roche

CYTODET-RO

Cytotoxicity Detection KitPLUS (LDH)

Thiazolylblau-Tetrazoliumbromid 98%

Sigma-Aldrich

M2128

Thiazolylblau-Tetrazoliumbromid

Shannon A Metcalf et al.
Peptides, 32(6), 1296-1302 (2011-05-12)
One of the possible mechanisms by which the weight-reducing surgical procedure ileal interposition (II) works is by increasing circulating levels of lower gut peptides that reduce food intake, such as glucagon like peptide-1 and peptide YY. However, since this surgery
Wenya Chen et al.
Bioscience, biotechnology, and biochemistry, 76(6), 1104-1109 (2012-07-14)
We have recently reported that oral gavage of a potato extract (Potein®) suppressed the food intake in rats. The satiating effect of the potato extract was compared in the present study to other protein sources, and the involvement of endogenous
X-M Wu et al.
Journal of animal physiology and animal nutrition, 96(2), 214-219 (2011-03-29)
Total parenteral nutrition (TPN) results in atrophy of the pancreas, while cholecystokinin (CCK) can significantly stimulate the exocrine pancreas in rodents. This study was designed to examine whether CCK may improve the atrophy of the pancreas in rats on TPN
Development of a CCK1R-membrane nanoparticle as a fish-out tool for bioactive peptides
Staljanssens D, et al.
Peptides, 68, 219-227 (2015)
Clémence Blouet et al.
PloS one, 7(12), e51898-e51898 (2012-12-20)
Previous evidence indicates that duodenal lipid sensing engages gut-brain neurocircuits to determine food intake and hepatic glucose production, but a potential role for gut-brain communication in the control of energy expenditure remains to be determined. Here, we tested the hypothesis
Alle zugehörigen Dokumente anzeigen

Fragen

Bewertungen

Kein Beurteilungswert

Aktive Filter

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.